Special Issue Title:

Targeted Therapies for Gynaecological Cancers

Deadline for manuscript submissions: 01 October 2020

Print Special Issue Flyer (3)

Special Issue Editor

  • Guest Editor

    Jacek R. Wilczynski, MDE-MailWebsite

    Department of Surgical and Oncological Gynecology, Medical University of Lodz, Lodz, Poland

    Interests: Gynaecological Surgery; Cancer Immunology; Reproductive Immunology

Special Issue Information

Dear Colleagues,

Nowadays, there are at least three fields of main concern in management of gynecologic cancers – treatment of advanced and recurrent cervical cancer, adjustment of proper adjuvant therapy to different genomic subtypes of endometrial cancer and finally fighting against chemoresistance of advanced and recurrent ovarian cancer. Despite no disputable advances in surgery, and traditional radio- and chemotherapy, still exists a group of patients who potentially could benefit from newly recognized drugs affecting various mechanisms of tumor development and its interplay with the host. These new targeted therapies are based on broad spectrum of activities targeting cell cycle checkpoints and DNA repair mechanisms, metabolic pathways, endoplasmic reticulum stress pathways, signaling pathways, tumor angiogenesis, immune checkpoint molecules, tumor-infiltrating cells or tumor stroma. Some of targeted therapies has already been approved for treatment, like bevacizumab or PARP-inhibitors, others are being tested in clinical trials, while plenty of new potential drugs are subjected to preclinical evaluation. Generally, targeted therapy is directed either against tumor components and growth regulatory mechanisms, or concentrates on enhancement of host antitumor activity. Both approaches could hopefully be used together to reassure maximal efficacy. Most of them could show effective anti-tumor activity under particular circumstances preconditioned by tumor histology, mutational status or metabolic behavior, what demands precise identification of the tumor type, but also generic and somatic mutations. Thus, new era of individualized therapy of gynecologic cancer patients has just begun. Moreover, new treatment modalities could be combined with both traditional chemo- and radiotherapy in order to boost their anti-tumor activity. The Special Issue of European Journal of Gynaecological Oncology is planned to cover these main topics of targeted therapies in gynecological cancers. I hope that the team of invited eminent specialists will show to the readers the fascinating landscape of approved, as well as most promising clinically tested and future drugs which could improve the outcome of our cancer patients.

Prof. Dr. Jacek R. Wilczynski

Guest Editor

Keywords

Targeted Therapy;Ovarian Cancer;Endometrial Cancer;Cervical Cancer

Manuscript Submission Information

Manuscripts should be submitted online by submit system. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Original articles, case reports or comprehensive reviews are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access journal published by MRE Press. Please visit the Instructions for Authors page before submitting a manuscript.The Article Processing Charge (APC) for publication in this open access journal is $1200. We normally offer a discount greater than 30% to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.

Share This Special Issue

Published Papers (2 papers)

Open Access Special Issue

The role of PARP inhibitors in ovarian cancer: therapeutic mechanisms and clinical data

Moo-Kon Song

DOI: 10.31083/j.ejgo.2021.02.2205

(This article belongs to the Special Issue Targeted Therapies for Gynaecological Cancers)

Abstract ( 258 ) PDF (301.38 kB) ( 110 )

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences